GPR151 Receptor Antibodies

GPR151 is an orphan class A GPCR that is highly enriched in the central nervous system and is particularly associated with specific populations of sensory neurons. The receptor is expressed predominantly in the habenula and in subsets of dorsal root ganglion neurons, with additional expression reported in the spinal cord and other brain regions. GPR151 is predominantly coupled to Gi/o proteins, and its activation is expected to inhibit adenylyl cyclase and modulate downstream MAPK and ion-channel signaling. The endogenous ligand of GPR151 has not yet been conclusively identified, and its pharmacology therefore remains poorly characterized. Functional studies suggest that GPR151 is involved in the regulation of nociception and sensory processing, particularly the transmission of noxious mechanical and thermal stimuli. Genetic deletion of GPR151 in experimental animals alters pain-related behaviors, supporting a role for the receptor in peripheral and central pain pathways. Because of its selective expression in sensory neurons, GPR151 has attracted interest as a potential target for the development of novel analgesic therapies, including treatments for chronic neuropathic and inflammatory pain. No approved drug or clinical-stage compound specifically targeting GPR151 is currently available, and validated selective agonists or antagonists remain limited. Overall, GPR151 represents a relatively unexplored orphan GPCR with a potentially attractive therapeutic profile for pain and sensory disorders, but its endogenous ligand, precise signaling mechanisms and pharmacological tractability remain to be established. For more information on GPR151 pharmacology please refer to the IUPHAR database. For further reading refer to: